- AU$40.72m
- AU$50.80m
- AU$123.87m
- 84
- 86
- 53
- 84
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.68 | ||
| PEG Ratio (f) | 0.06 | ||
| EPS Growth (f) | 37.28% | ||
| Dividend Yield (f) | 14.29% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.99 | ||
| Price to Tang. Book | 4.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.32 | ||
| EV to EBITDA | 10.46 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.52% | ||
| Return on Equity | 4.85% | ||
| Operating Margin | 1.92% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.12 | 21.71 | 66.99 | 117.34 | 123.87 | 188.2 | 222.1 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +251.84 | +94.44 | -74.49 | +484.42 | +19.44 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vitura Health Limited is engaged in a diversified digital health business. The Company, through its subsidiaries, operates businesses, including Burleigh Heads Cannabis, Canview, Doctors on Demand, Cortexa, CDA Clinics, and Cannadoc. Its sales and distribution segment covers the sale and distribution of medical products, including medicinal cannabis, psychedelic drugs and smoking cessation products, and potentially others. Its clinics and services segment covers the provision of medical consultations and related services. Burleigh Heads Cannabis operates the prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from about 60 international and domestic brands. Doctors on Demand is a telehealth platform business that provides primary health solutions. It also operates the Candor Medical brand, which provides prescription treatments, including access to medicinal cannabis.
Directors
- Shane Tanner NEC
- Rodney Cocks CEO
- Thomas Howitt CFO
- Guy Headley DRC
- Benjamin Jansen DRC
- Kurt Schmidt DRC (64)
- Marcia Walker DRC
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 27th, 2018
- Public Since
- November 7th, 2019
- No. of Shareholders
- 3,634
- No. of Employees
- 119
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 581,653,062
- Address
- Suite 8, Melbourne, 3141
- Web
- https://www.vitura.com.au/
- Phone
- +61 300799491
- Auditors
- Pilot Partners
Upcoming Events for VIT
Similar to VIT
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Vitura Health share price?
As of Today at 24:00 UTC, shares in Vitura Health are trading at AU$0.07. This share price information is delayed by 15 minutes.
How has the Vitura Health share price performed this year?
Shares in Vitura Health last closed at AU$0.07 and the price had moved by -58.82% over the past 365 days. In terms of relative price strength the Vitura Health share price has underperformed the ASX All Ordinaries Index by -59.44% over the past year.
What are the analyst and broker recommendations for Vitura Health?
The overall consensus recommendation for Vitura Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vitura Health dividend yield?
Vitura Health does not currently pay a dividend.
Does Vitura Health pay a dividend?
Vitura Health does not currently pay a dividend.
When does Vitura Health next pay dividends?
Vitura Health does not currently pay a dividend.
How do I buy Vitura Health shares?
To buy shares in Vitura Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vitura Health?
As of the previous close price of AU$0.07, shares in Vitura Health had a market capitalisation of AU$40.72m.
Where are Vitura Health shares listed?
Here are the trading details for Vitura Health:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: VIT
What kind of share is Vitura Health?
Based on an overall assessment of its quality, value and momentum Vitura Health is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vitura Health share price forecast for 2025?
The analyst consensus target price for shares in Vitura Health is AU$0.70. That is 900% above the last closing price of AU$0.07.
Analysts covering Vitura Health currently have a consensus Earnings Per Share (EPS) forecast of AU$0.04 for the next financial year.
Find out moreWhat is the trend in the Vitura Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vitura Health. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -38.36%.
As of the last closing price of AU$0.07, shares in Vitura Health were trading -17.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vitura Health PE Ratio?
The Vitura Health PE ratio based on its reported earnings over the past 12 months is 1.68. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vitura Health?
Vitura Health's management team is headed by:
- Shane Tanner - NEC
- Rodney Cocks - CEO
- Thomas Howitt - CFO
- Guy Headley - DRC
- Benjamin Jansen - DRC
- Kurt Schmidt - DRC
- Marcia Walker - DRC